This underlines the importance of elastin degradation as a potential biomarker in COPD, however, the desmosine technology identifies non-specific elastin fragments that are being generated through many different processes, both physiological and pathophysiological. This evidence concerns the gene ELN and chronic obstructive pulmonary disease.